Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of chemotherapy-free treatment regimens for patients with mantle cell lymphoma (MCL). Prof. Wang highlights the success of a chemotherapy-free cohort in the WINDOW-2 trial (NCT03710772) which investigated ibrutinib, rituximab and venetoclax in younger patients with MCL in the frontline setting. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.